HUE058049T2 - Eljárás N-((1R,2S,SR)-5-(terc-butilamino)-2-((S)-3-(7-terc-butilpirazolo[1,5-A][1,3,5] triazin-4-ilamino)-2-oxopirrolidin-1-il)ciklohexil)acetamid elõállítására - Google Patents

Eljárás N-((1R,2S,SR)-5-(terc-butilamino)-2-((S)-3-(7-terc-butilpirazolo[1,5-A][1,3,5] triazin-4-ilamino)-2-oxopirrolidin-1-il)ciklohexil)acetamid elõállítására

Info

Publication number
HUE058049T2
HUE058049T2 HUE18785785A HUE18785785A HUE058049T2 HU E058049 T2 HUE058049 T2 HU E058049T2 HU E18785785 A HUE18785785 A HU E18785785A HU E18785785 A HUE18785785 A HU E18785785A HU E058049 T2 HUE058049 T2 HU E058049T2
Authority
HU
Hungary
Prior art keywords
tert
butylpyrazolo
oxopyrrolidin
triazin
ylamino
Prior art date
Application number
HUE18785785A
Other languages
English (en)
Inventor
Burcu Selin Aytar
Alina Borovika
Collin Chan
Joerg Deerberg
Nathan R Domagalski
Martin D Eastgate
Yu Fan
Michael David Bengt Fenster
Robert V Forest
Francisco Gonzalez-Bobes
Rebecca A Green
Matthew R Hickey
Nathaniel David Kopp
Cruz Thomas E La
Kathleen Lauser
Hong Geun Lee
David K Leahy
Helen Y Luo
Thomas M Razler
Scott A Savage
Chris Sfouggatakis
Maxime C D Soumeillant
Serge Zaretsky
Bin Zheng
Ye Zhu
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HUE058049T2 publication Critical patent/HUE058049T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00Thiocarboxylic acids
    • C07C327/20Esters of monothiocarboxylic acids
    • C07C327/22Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
HUE18785785A 2017-07-20 2018-07-19 Eljárás N-((1R,2S,SR)-5-(terc-butilamino)-2-((S)-3-(7-terc-butilpirazolo[1,5-A][1,3,5] triazin-4-ilamino)-2-oxopirrolidin-1-il)ciklohexil)acetamid elõállítására HUE058049T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762534908P 2017-07-20 2017-07-20

Publications (1)

Publication Number Publication Date
HUE058049T2 true HUE058049T2 (hu) 2022-06-28

Family

ID=63834628

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18785785A HUE058049T2 (hu) 2017-07-20 2018-07-19 Eljárás N-((1R,2S,SR)-5-(terc-butilamino)-2-((S)-3-(7-terc-butilpirazolo[1,5-A][1,3,5] triazin-4-ilamino)-2-oxopirrolidin-1-il)ciklohexil)acetamid elõállítására

Country Status (22)

Country Link
US (2) US11254679B2 (hu)
EP (1) EP3655395B1 (hu)
JP (1) JP2020527576A (hu)
KR (1) KR20200031656A (hu)
CN (1) CN110933946A (hu)
AU (1) AU2018304290B2 (hu)
BR (1) BR112020000418A2 (hu)
CA (1) CA3070423A1 (hu)
CY (1) CY1125023T1 (hu)
DK (1) DK3655395T3 (hu)
EA (1) EA202090346A1 (hu)
ES (1) ES2907640T3 (hu)
HR (1) HRP20220264T8 (hu)
HU (1) HUE058049T2 (hu)
IL (2) IL293088A (hu)
LT (1) LT3655395T (hu)
PL (1) PL3655395T3 (hu)
PT (1) PT3655395T (hu)
RS (1) RS62941B1 (hu)
SG (1) SG11202000441QA (hu)
SI (1) SI3655395T1 (hu)
WO (1) WO2019018592A2 (hu)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3088542A1 (en) * 2018-01-22 2019-07-25 Bristol-Myers Squibb Company Compositions and methods of treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4546923B2 (ja) * 2003-05-30 2010-09-22 チョンウェ ファーマ コーポレーション ベータストランドミメティックスおよびこれに関連した方法
US7629351B2 (en) * 2006-07-28 2009-12-08 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino) pyrrolidin-1-yl)cyclohexyl)acetamide and other modulators of chemokine receptor activity, crystalline forms and process
US7671062B2 (en) * 2006-07-28 2010-03-02 Bristol-Myers Squibb Company Modulators of chemokine receptor activity, crystalline forms and process
CN100593536C (zh) * 2007-01-09 2010-03-10 吉尔生化(上海)有限公司 一种n-芴甲氧羰基-n-三苯甲基-d-谷氨酰胺的合成法
US8383812B2 (en) * 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
EP3974563A1 (en) * 2011-12-28 2022-03-30 Chugai Seiyaku Kabushiki Kaisha Cyclic peptides

Also Published As

Publication number Publication date
SG11202000441QA (en) 2020-02-27
LT3655395T (lt) 2022-03-10
IL272034A (en) 2020-03-31
IL272034B (en) 2022-06-01
JP2020527576A (ja) 2020-09-10
CN110933946A (zh) 2020-03-27
PL3655395T3 (pl) 2022-03-07
US11254679B2 (en) 2022-02-22
RS62941B1 (sr) 2022-03-31
CY1125023T1 (el) 2023-03-24
EP3655395A2 (en) 2020-05-27
AU2018304290B2 (en) 2022-11-17
DK3655395T3 (da) 2022-03-07
ES2907640T3 (es) 2022-04-25
US20200223852A1 (en) 2020-07-16
AU2018304290A8 (en) 2020-04-02
AU2018304290A1 (en) 2020-03-05
CA3070423A1 (en) 2019-01-24
SI3655395T1 (sl) 2022-04-29
PT3655395T (pt) 2022-02-22
HRP20220264T1 (hr) 2022-05-13
KR20200031656A (ko) 2020-03-24
IL293088A (en) 2022-07-01
WO2019018592A2 (en) 2019-01-24
HRP20220264T8 (hr) 2022-05-27
EP3655395B1 (en) 2021-12-01
US20220177482A1 (en) 2022-06-09
WO2019018592A3 (en) 2019-02-28
EA202090346A1 (ru) 2020-08-18
BR112020000418A2 (pt) 2020-07-14

Similar Documents

Publication Publication Date Title
PT3458456T (pt) Preparação de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidino-1-carboxamida
IL262003A (en) Liquid formulations of (s)-n-(5-((r)-2-(5,2-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[5,1-a]pyrimidin-3-yl)-3 -Hydroxypyrrolidine-1-carboxamide
IL290905A (en) Crystal form of (s)–n-(5–)–2–(r))5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-a]pyrimidine-3-yl)-3 -Hydroxypyrrolidine-1-carboxamide hydrogen sulfate
WO2018042343A3 (en) Compounds that inhibit 3c and 3cl proteases and methods of use thereof
SI2885266T1 (sl) Postopek za pripravo (2Z,5Z)-5-(3-kloro-4-((R)-2,3-dihidroksipropoksi) benziliden)-2-(propilimino)-3-(O-tolil)tiazolidin-4-on in v omenjenem postopku uporabljena vmesna spojina
NZ630033A (en) Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-indazol-5-yloxy)benzyl)urea hydrochloride
PL3655395T3 (pl) Proces otrzymywania n-((1r,2s,sr)-5-(tert-butyloamino)-2-((s)-3-(7-tert-butylopirazolo[1,5-a][1,3,5]triazyn-4-yloamino)-2-oksopirolidyn-1-ylo)cykloheksylo)acetamidu
EP3927689A4 (en) PROCESSES FOR THE PREPARATION OF (3R,4R)-1-BENZYL-N,4-DIMETHYLPIPERIDINE-3-AMINE OR A SALT THEREOF AND PROCESSES FOR THE PREPARATION OF TOFACITINIB THEREFORE
AU2017900496A0 (en) Compounds for Enhancing the Permeation of Active Pharmaceutical Ingredients through Skin